GSK promotes Jean Stephenne to chairman, biologicals

pharmafile | March 15, 2010 | Appointment | Research and Development, Sales and Marketing |  GlaxoSmithKline, appointment, research and development, sales and marketing 

GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.

He is currently president and general manager of the unit, which is headquartered in Belgium.

The move is part of a succession plan for the vaccines business, which will see R&D chairman Dr Moncef Slaoui gradually assume operational responsibility for GSK Biologicals over the next two years.

GSK’s chief executive Andrew Witty said: “Succession planning is fundamental to GSK’s long-term success and today’s changes are clear evidence that we are taking proactive steps to maintain excellent leadership in our business.

“Jean has built a world-leading vaccines business and as chairman will continue to be instrumental in driving forward our public health agenda. Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today.

“These changes will ensure continued strong focus on delivery and development of this pipeline; they also reflect the more holistic approach we are taking to R&D capital investment.”